Cargando…

Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease

BACKGROUND: In order to increase treatment choices for patients with Parkinson disease (PD), we performed a retrospective assessment of adverse events associated with a novel once-daily extended-release (ER) formulation versus the standard immediate-release (IR) of the nonergolinic dopamine agonist,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Zhengze, Kong, Deping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112990/ https://www.ncbi.nlm.nih.gov/pubmed/30142750 http://dx.doi.org/10.1097/MD.0000000000011316

Ejemplares similares

Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
por: Eisenreich, Wolfram, et al.
Publicado: (2010)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations
por: Xiang, Wei, et al.
Publicado: (2018)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
por: Hametner, Eva-Maria, et al.
Publicado: (2012)

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole
por: Salawu, Fatai Kunle
Publicado: (2012)

Auditory Musical Hallucinations Associated With Extended-Release Pramipexole in an Elderly Patient With Parkinson's Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2014)

Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study
por: Zhou, Haiyan, et al.
Publicado: (2021)

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
por: Hauser, Robert A., et al.
Publicado: (2014)

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
por: Hauser, R A, et al.
Publicado: (2014)

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
por: Faddoul, Lama, et al.
Publicado: (2018)

Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?
por: Solla, Paolo, et al.
Publicado: (2013)

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Changes in Pramipexole Utilization after Introduction of the Extended-Release Formulation: A Nationwide Study in Taiwan
por: Chan, K. Arnold, et al.
Publicado: (2020)

Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate-release/extended release
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008)

Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease
por: Piedad, John C. P., et al.
Publicado: (2012)

Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate
por: Vaidya, Varun, et al.
Publicado: (2012)

Pharmacokinetics of immediate release, extended release, and gastric retentive gabapentin formulations in healthy adults
por: Swearingen, Dennis, et al.
Publicado: (2018)

Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Analysis of pramipexole dose–response relationships in Parkinson’s disease
por: Wang, Ying, et al.
Publicado: (2016)

Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Sun, Yongqi, et al.
Publicado: (2022)

Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
por: Ena, Javier, et al.
Publicado: (2012)

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States
por: Iwanicki, Janetta L., et al.
Publicado: (2016)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy
por: Espay, Alberto J., et al.
Publicado: (2017)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)

The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
por: Xu, H. R., et al.
Publicado: (2012)

Patterns of Immediate-Release and Extended-Release Opioid Analgesic Use in the Management of Chronic Pain, 2003-2014
por: Hwang, Catherine S., et al.
Publicado: (2018)

Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
por: Kano, Osamu, et al.
Publicado: (2008)

Retracted: Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Comparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites
por: Gamboa, Jorge L., et al.
Publicado: (2016)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

Metformin extended‐release versus immediate‐release: An international, randomized, double‐blind, head‐to‐head trial in pharmacotherapy‐naïve patients with type 2 diabetes
por: Aggarwal, Naresh, et al.
Publicado: (2017)

Efficacy of pramipexole on quality of life in patients with Parkinson’s disease: a systematic review and meta-analysis
por: Li, Tao, et al.
Publicado: (2022)

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Possible effects of pramipexole on neck muscles in a patient with Parkinson's disease
por: Filippi, Roberto, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dahp38695n0f51fg5qimi843b9